[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.89.187. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1976

BCG Immunoprophylaxis of Recurrent Herpes Progenitalis

Author Affiliations

From the Divisions of Dermatology, UCLA Center for the Health Sciences and the Veterans Administration Wadsworth Hospital Center, Los Angeles.

Arch Dermatol. 1976;112(10):1410-1415. doi:10.1001/archderm.1976.01630340028008
Abstract

• Thirty-eight patients with severe, recurrent herpes progenitalis were treated by immunoprophylaxis with repeated BCG inoculations. Results of the study demonstrated no significant prophylactic benefit of BCG when contrasted to other homologous or heterologous antigens or to control patients receiving placebos. Caution is warranted in the use of homologous vaccines from Germany because theoretically, tumor growth might be enhanced by immunologic means, although the vaccine apparently has no intrinsic oncogenic qualities.

(Arch Dermatol 112:1410-1415, 1976)

×